Research led by the UConn School of Medicine and JAX shows that senescence, a cellular aging process, is associated with an aggressive form of multiple sclerosis (MS). The finding explains a mechanism for MS disease progression as well as indicating a promising avenue for therapy development.
The age of onset of multiple sclerosis (MS) is usually early or mid-adulthood, so it’s not thought of as a disease of aging. MS is caused by an autoimmune attack on nerve cells in the central nervous system, leading to a loss of the fatty tissue that surrounds them (demyelination) and loss of function. There is no current cure, but a promising avenue for treatment is to induce re-myelination of the nerve cells using neural stem and progenitor cells that can regenerate lost tissue. Now, research suggests that certain cells in MS patients have all the hallmarks of age-related senescence, with important implications for therapy development.
In a paper published in Proceedings of the National Academy of Sciences, “Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis,” a team led by Associate Stephen Crocker, Ph.D., from the University of Connecticut School of Medicine in collaboration with Jackson Laboratory (JAX) analyzed neural progenitor cells (NPCs) and oligodendrocyte precursor cells (OPCs) from posthumous brain tissues from patients who had progressive MS. In healthy individuals, NPCs promote OPC maturation and differentiation into oligodendrocytes, which form the myelin sheaths needed for proper neuron function.
In MS patients, however, the researchers found that the NPCs exhibited the molecular hallmarks of senescence. NPCs developed from induced pluripotent stem cells (iPSCs) from patients also express cellular senescence markers. Given that white matter lesions in MS patients contain immature, non-functional oligodendrocytes, the researchers investigated the possible connection between the two findings. Using an in vitro system, they showed that iPSC-derived NPCs from patients were less able to support OPC maturation or provide protection from demyelination, indicating that prematurely senescent NPCs likely play a role in progressive MS.
Administering rapamycin, which blocks senescence pathways, restored NPC function and OPC maturation. Targeting cellular senescence may, therefore, provide a way to prevent demyelination in vivo, and perhaps even allow re-myelination and restoration of function. Thus, reversing premature cellular aging offers a promising new approach for treating progressive MS.